Supreme Court Upholds , FDA Regulation on Popular , Abortion Drug Mifepristone.<br />On June 13, the Supreme Court ruled against a group of <br />doctors who challenged the Food and Drug Administration's <br />(FDA) regulations on the abortion pill mifepristone.<br />CBS reports that the case once again highlighted <br />abortion access following the conservative <br />majority decision to overturn Roe v. Wade in 2022.<br />The court ruled unanimously that the group of <br />anti-abortion rights doctors and medical associations <br />lacked the legal right to challenge the FDA. .<br />However, the court also did not address <br />whether the FDA's decision to relax the <br />rules for mifepristone's use were lawful. .<br />The latest ruling was authored <br />by Justice Brett Kavanaugh. .<br />Under Article III of the Constitution, <br />a plaintiff's desire to make a drug <br />less available for others does <br />not establish standing to sue. , Justice Brett Kavanaugh writing for the court, via CBS.<br />Nor do the plaintiffs' other <br />standing theories suffice. <br />Therefore, the plaintiffs lack <br />standing to challenge FDA's actions, Justice Brett Kavanaugh writing for the court, via CBS.<br />CBS reports that the ruling does not impact other <br />challenges to the FDA's standing on mifepristone, <br />while preserving access to the popular abortion medication.<br />In 2016 and 2021, the FDA took steps to widen access <br />to mifepristone, which has been taken by over <br />5 million patients since first being approved in 2000.<br />Those steps included allowing the drug to be taken up to 10 <br />weeks into a pregnancy, reducing the number of in-person <br />doctor visits and permitting it to be sold through the mail.
